Qiagen (QGEN) FY Conference June 09, 2025 09:00 AM ET Speaker0 Hi, good morning, everyone. I'm Matt Sykes, Life Science Tools and Diagnostics Analyst at Goldman Sachs. I have the pleasure of being joined by Roland Saker, CFO and John Gallardi, Head of IR. Roland, John, thanks for being here. Speaker1 Thank you. Speaker2 Thank you. Speaker0 Maybe we could start out, just given the current environment we're in, which is continues to be challenging, maybe just talk through sort of the durability of your end ma ...

Qiagen (QGEN) 2025 Conference June 05, 2025 09:55 AM ET Speaker0 Okay. Thanks. Speaker1 I think, Roland, maybe I'll just start off with a higher level question. You've done a lot in terms of reshaping the portfolio. You're buying stock. You've got, you know, expanding margins. You're you're doing all the right things. I think are there areas areas you think you could be doing more and what do you Speaker2 think is Speaker1 most underappreciated right now? Speaker2 First thing that I'm going to do is buy a n ...

Qiagen (QGEN) 2025 Conference May 14, 2025 01:00 PM ET Speaker0 On how the quarter played out relative to your expectations, but what were the big surprises? What really stood out to you? Speaker1 No. Again, first of thanks for having us. It's always a pleasure to be here. And well, as you said, Q1 was actually a very strong start for QIAGEN into the year. We clearly came in with a 7% growth rate revenue wise. We were able not only to beat our EPS guidance for the quarter, we also feel quite comfortable to ...

Qiagen (QGEN) Q1 2025 Earnings Call May 08, 2025 09:00 AM ET Company Participants John Gilardi - Vice President & Head of Corporate CommunicationsThierry Bernard - CEO, MD & Member of Management BoardRoland Sackers - CFO, MD & Member of Management BoardDoug Schenkel - Managing DirectorTycho Peterson - Managing DirectorMichael Ryskin - Managing DirectorJan Koch - VP - Equity ResearchDaniel Brennan - Managing DirectorCasey Woodring - Vice President - Equity Research Conference Call Participants Dan Leonard - ...

Qiagen (QGEN) Q1 2025 Earnings Call May 08, 2025 09:00 AM ET Speaker0 Ladies and gentlemen, thank you for standing by. I'm Lisa, your PGI call operator. Welcome, and thank you for joining QIAGEN's Q1 twenty twenty five Earnings Conference Call Webcast. At this time, all participants are in a listen only mode. Please be advised that this call is being recorded at QIAGEN's request and will be made available on their Internet site. The prepared remarks will be followed by a question and answer session. At this ...

Core Insights - QIAGEN N.V. reported first-quarter 2025 adjusted earnings per share (EPS) of 55 cents, a 17% increase year-over-year, surpassing the Zacks Consensus Estimate by 10% [1][2] - The company’s net sales for the quarter were $483.5 million, reflecting a 5.4% increase from the previous year and exceeding the Zacks Consensus Estimate by 4.8% [3] Revenue Breakdown - Sample technologies revenues decreased by 3% to $150 million, while diagnostic solutions revenues increased by 9% to $187 million, driven by strong demand for QuantiFERON and QIAstat-Dx [4] - PCR/Nucleic acid amplification revenues rose by 13% to $76 million, and other revenues surged by 57% to $18 million [5] Operational Performance - The adjusted gross profit increased by 4.9% to $322.2 million, with a gross margin of 66.6%, down 29 basis points year-over-year [6] - Adjusted operating income grew by 20% to $140.4 million, with an operating margin expansion of 354 basis points to 29% [7] Financial Position - QIAGEN ended the first quarter with cash and short-term investments totaling $963.4 million, down from $1.20 billion at the end of the previous quarter [9] - The company reported long-term debt of $1.35 billion, slightly up from $1.34 billion in the prior quarter [10] Outlook - For 2025, QIAGEN expects net sales to increase by about 4% at constant exchange rates, with adjusted EPS projected at $2.35 [11] - The company anticipates second-quarter net sales to rise by approximately 5% at constant exchange rates, with adjusted EPS expected to be at least 60 cents [12] Overall Assessment - QIAGEN's first-quarter results indicate a resilient portfolio with strong recurring revenues, despite challenges in gross margins and rising costs [13][15] - The diagnostic solutions segment showed the highest growth, supported by the adoption of new technologies [14]

Wall Street analysts forecast that Qiagen (QGEN) will report quarterly earnings of $0.50 per share in its upcoming release, pointing to a year-over-year increase of 6.4%. It is anticipated that revenues will amount to $464.04 million, exhibiting an increase of 1.1% compared to the year-ago quarter.The current level reflects no revision in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial project ...